Chapter title |
Leukotriene Receptor Antagonists and Antiallergy Drugs
|
---|---|
Chapter number | 72 |
Book title |
Pharmacology and Therapeutics of Asthma and COPD
|
Published in |
Handbook of experimental pharmacology, January 2016
|
DOI | 10.1007/164_2016_72 |
Pubmed ID | |
Book ISBNs |
978-3-31-952173-2, 978-3-31-952175-6
|
Authors |
Tsutomu Tamada, Masakazu Ichinose, Tamada, Tsutomu, Ichinose, Masakazu |
Abstract |
As one of the candidates of the therapeutic strategy for asthma in addition to inhaled corticosteroids (ICS), leukotriene receptor antagonists (LTRAs) are known to be useful for long-term management of asthma patients complicated by allergic rhinitis (AR) or exercise-induced asthma (EIA). Currently available LTRAs are pranlukast hydrate, zafirlukast, and montelukast. These LTRAs have a bronchodilator action and inhibit airway inflammation, resulting in a significant improvement of asthma symptoms, respiratory function, inhalation frequency of as-needed inhaled β2-agonist, airway inflammation, airway hyperresponsiveness, dosage of ICSs, asthma exacerbations, and patients' QOL. Although cys-LTs are deeply associated with the pathogenesis of asthma, LTRAs alone are less effective compared with ICS. However, the effects of LTRAs in combination with ICS are the same as those of LABAs in combination with ICS in steroid-naïve asthmatic patients. Concerning antiallergy drugs other than LTRAs, some mediator-release suppressants, H1 histamine receptor antagonists (H1RAs), thromboxane A2 (TXA2) inhibitors/antagonists, and Th2 cytokine inhibitor had been used mainly in Japan until the late 1990s. However, the use of these agents rapidly decreased after ICS/long acting beta agonist (LABA) combination was introduced and recommended for the management of asthma in the early 2000s. The effectiveness of other antiallergic agents on asthma management seems to be quite limited, and the safety of oral antiallergic agents has not been demonstrated in fetuses during pregnancy. Further effectiveness studies are needed to determine the true value of these orally administered agents in combination with ICS as an anti-asthma treatment. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 37 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 7 | 19% |
Professor | 4 | 11% |
Student > Ph. D. Student | 4 | 11% |
Student > Doctoral Student | 3 | 8% |
Student > Master | 2 | 5% |
Other | 5 | 14% |
Unknown | 12 | 32% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 10 | 27% |
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 8% |
Immunology and Microbiology | 3 | 8% |
Psychology | 2 | 5% |
Nursing and Health Professions | 1 | 3% |
Other | 5 | 14% |
Unknown | 13 | 35% |